Genentech’s Subcutaneous Tecentriq Shows Non-Inferiority To I.V. Formulation

Developers of the top-selling checkpoint inhibitor therapies for cancer are competing to bring the first subcutaneous formulation to market and Genentech, Inc. announced a major step in that goal on 2 August, revealing that a pivotal study testing a subcutaneous formulation of its anti-PD-L1 therapy Tecentriq (atezolizumab) versus the current intravenous formula met the primary endpoints.

The Roche Holding AG subsidiary did not provide any numerical data from the Phase Ib/III IMscin001 trial, but said its subcutaneous formulation showed non-inferior levels of drug in patients’...